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ARTICLE OPEN
Stability of the frequent COPD exacerbator in the general
population: A Danish nationwide register-based study
Mette Reilev1, Jesper Lykkegaard1, Anders Halling2, Jørgen Vestbo3,4, Jens Søndergaard1 and Anton Pottegård5
Exacerbation frequency is central in treatment strategies for chronic obstructive pulmonary disease. However, whether chronic
obstructive pulmonary disease patients from the general population with frequent exacerbations continue to have frequent
exacerbations over an extended period of time is currently unknown. In this study, we aimed to investigate the stability of the
frequent exacerbator in a population-based setting. To this end, we conducted a nationwide register-based descriptive study with a
10-year follow-up period of chronic obstructive pulmonary disease patients with at least one medically treated exacerbation in 2003.
Each subsequent year, we divided the population into frequent, infrequent and non-exacerbators and quantiﬁed the ﬂow between
categories. Further, we estimated the percentage of frequent exacerbators at baseline who stayed in this category each year during a
5-year follow-up. We identiﬁed 19,752 patients with chronic obstructive pulmonary disease and an exacerbation in 2003. Thirty
percent were frequent exacerbators. Overall, the majority of exacerbators in 2003 were non-exacerbators in the following years (60%
in 2004 increasing to 68% in 2012). Approximately half of frequent exacerbators in one year experienced a decrease in exacerbation
frequency and had either zero or one exacerbation in the subsequent year. This pattern was stable throughout follow-up. During a 5-
year follow-up period, a substantial proportion (42%) of frequent exacerbators in 2003 had no additional years as frequent
exacerbators, while the minority (6%) remained in this category each year. In conclusion, the rate of exacerbations shows
considerable variation over time among chronic obstructive pulmonary disease patients in the general population. This might hold
implications for chronic obstructive pulmonary disease treatment guidelines and their practical application.
npj Primary Care Respiratory Medicine  (2017) 27:25 ; doi:10.1038/s41533-017-0029-7
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is characterized by
recurrent exacerbations, deﬁned as episodes of “worsening of
respiratory symptoms that are beyond the normal day-to-day
variation and lead to a change in treatment”.1 Exacerbations have
considerable impact on patients and result in increased mortality
as well as augmented use of medication, rehabilitation and
hospitalizations.2–7
Exacerbation frequency is a key component in determining
treatment strategies for COPD. Most guidelines classify individuals
by the number of exacerbations in the previous year, with the
underlying assumption that frequent exacerbators remain in this
category.1 To some extent, this assumption is supported by studies
showing that the number of exacerbations in the previous
year is the best predictor of future exacerbations.8, 9 In addition,
the ECLIPSE study showed that the majority of patients
without exacerbations remained stable over time, at least within
the 3-year study period.9, 10 However, these studies included
selected patients with moderate to very severe COPD in a hospital
setting11, 12 who are known to differ substantially from COPD
patients in primary care.13 Little is known about the stability of the
exacerbation rate in the general COPD population over an
extended period of time.
This study aimed at evaluating the stability of the frequent
exacerbator status in the general COPD population in Denmark.
RESULTS
Among all Danish citizens who were 55 years or older (1.5 million),
we identiﬁed 19,752 patients with at least one COPD exacerbation in
2003. The median age at cohort entry was 71 years (interquartile
range 64–77), 57% were women, and 57% had experienced an
exacerbation within the last 5 years (Table 1). 5917 patients (30%)
were classiﬁed as frequent exacerbators and 13,835 (70%) as
infrequent exacerbators; 50% of all exacerbators were classiﬁed as
severe exacerbators. Compared to infrequent exacerbators, those
classiﬁed as frequent exacerbators were more frequently previous
exacerbators (75 vs. 49%) and used more respiratory drugs (Table 1).
As per inclusion criteria, all individuals had one or more
exacerbations in 2003, of which 50% were classiﬁed as severe
exacerbators. In 2004, 60% of those alive had no exacerbations and
this proportion increased gradually to 68% in 2012 (Fig. 1). The
proportion of exacerbators that were classiﬁed as severe exacer-
bators declined slightly throughout follow-up, to 43% in 2012.
The overall mortality among exacerbators in 2003 within the
ﬁrst year of follow-up was 13.2% (Fig. 1). The annual mortality rate
was largely stable at around 11% during follow-up, with 65%
having died by the end of 2012. Within the categories of non-
exacerbators, infrequent exacerbators, frequent exacerbators and
severe exacerbators, the annual mortality rate was likewise stable
during the 10-year follow-up and was found to increase with
increasing exacerbation rate (8, 13, 18, and 23%, respectively)
(Table 2).
Received: 11 October 2016 Revised: 14 March 2017 Accepted: 21 March 2017
1The Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense DK-5000, Denmark; 2Department of Clinical Sciences Malmö,
Center for Primary Health Care Research, Lund University, Lund, Sweden; 3Department of Respiratory Medicine, Odense University Hospital, Odense DK-5000, Denmark; 4Division
of Infection, Immunity and Respiratory Medicine, Manchester Academic Health Science Centre, University of Manchester and University Hospital South Manchester NHS
Foundation Trust, Manchester M23 9LT, UK and 5Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense DK-5000, Denmark
Correspondence: Mette Reilev (mreilev@health.sdu.dk)
www.nature.com/npjpcrm
Published in partnership with Primary Care Respiratory Society UK
Throughout follow-up, about half of those classiﬁed as frequent
exacerbators in 1 year, were classiﬁed as frequent exacerbators in the
subsequent year (Fig. 2). Overall, a large proportion was classiﬁed as
non-exacerbators from 2004 onwards (Fig. 2). The sensitivity analysis
including the recommended ﬁrst-line antibiotic treatment
(amoxicillin combined with enzyme inhibitor) in the deﬁnition of
exacerbations did not change the observed pattern (supplementary
Fig. 1). When including all antibiotics used in the treatment of
respiratory infections, a slightly larger proportion of those classiﬁed
as frequent exacerbators in 1 year remained in this category in the
subsequent year (supplementary Fig. 2). When restricting to
individuals classiﬁed as frequent exacerbators at baseline, a largely
similar pattern was observed (supplementary Fig. 3).
We performed a post-hoc analysis of exacerbators in 2003,
restricted to those who were also classiﬁed as frequent exacer-
bators in 2002. In this population, a slightly larger proportion of
those classiﬁed as frequent exacerbators in 1 year stayed in this
category in the subsequent year, but the overall pattern was
similar to that of the primary analysis (supplementary Fig. 4).
Lastly, we performed a similar analysis, including mortality as a
separate category (supplementary Fig. 5) which, in line with
Table 2, illustrated that while the mortality was slightly higher
among frequent exacerbators, the categories of infrequent
exacerbators and non-exacerbators also contributed substantially
to the mortality from 2004 and onwards.
The stability of frequent exacerbators at an individual level was
assessed during a 5-year follow-up, restricting to 10,703 indivi-
duals (54%) that had ﬁve or more years of eligible follow-up. This
restriction more often excluded those classiﬁed as severe
exacerbators at baseline compared to frequent and infrequent
Table 1. Baseline characteristics of the study population (31 December 2003)







Male 8452 (42.8%) 5848 (42.3%) 2604 (44.0%) 4379 (44.4%)
Female 11,300 (57.2%) 7987 (57.7%) 3313 (56.0%) 5474 (55.6%)
Age (years)
Median (IQR) 71 (64–77) 70 (63–77) 71 (65–77) 72 (66–78)
55–69 years 8877 (44.9%) 6366 (46.0%) 2511 (42.4%) 3688 (37.4%)
70–79 years 7686 (38.9%) 5194 (37.5%) 2492 (42.1%) 4259 (43.2%)
80 + years 3189 (16.1%) 2275 (16.4%) 914 (15.4%) 1906 (19.3%)
Previous exacerbations
No 8595 (43.5%) 7098 (51.3%) 1497 (25.3%) 3729 (37.8%)
Yes 11,157 (56.5%) 6737 (48.7%) 4420 (74.7%) 6124 (62.2%)
Drug classes used
1 3574 (18.1%) 3058 (22.1%) 516 (8.7%) 1287 (13.1%)
2 5552 (28.1%) 4231 (30.6%) 1321 (22.3%) 2244 (22.8%)
3+ 10,561 (53.5%) 6483 (46.9%) 4078 (68.9%) 6284 (63.8%)
Medication
ICS 10,814 (54.7%) 7254 (52.4%) 3560 (60.2%) 5330 (54.1%)
LAMA 7007 (35.5%) 4306 (31.1%) 2701 (45.6%) 4286 (43.5%)
LABA 6512 (33.0%) 4181 (30.2%) 2331 (39.4%) 3572 (36.3%)
SABA 12,906 (65.3%) 8837 (63.9%) 4069 (68.8%) 6621 (67.2%)
SAMA 1254 (6.3%) 717 (5.2%) 537 (9.1%) 887 (9.0%)
Combination (SABA +
SAMA)
8442 (42.7%) 5100 (36.9%) 3342 (56.5%) 5499 (55.8%)
Combination (LABA+ICS) 6940 (35.1%) 4484 (32.4%) 2456 (41.5%) 3663 (37.2%)
Individuals are classiﬁed according to rate and severity of exacerbations in year 2003
Non-exacerbators (0 exacerbations in the given year)
Infrequent exacerbators (1 exacerbation in the given year)
Frequent exacerbators (≥2 exacerbations in the given year)
Severe exacerbators (≥1 hospitalization with COPD in the given year)
ICS inhaled corticosteroids, LAMA long-acting muscarinic antagonists, LABA long-acting beta-agonists, SAMA short-acting muscarinic antagonists, SABA short-
acting beta-agonists
Fig. 1 Distribution of exacerbators over time. Histogram 1 illustrates
the number of frequent exacerbators, infrequent exacerbators and
non-exacerbators each year among exacerbators at baseline (2003).
Red Frequent exacerbators (≥2 exacerbations in the given year); Blue
Infrequent exacerbators (1 exacerbation in the given year); Green
Non-exacerbators (0 exacerbations in the given year); Grey Lost to
follow-up (died or migrated)
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exacerbators (61 vs. 55 vs. 42% excluded). Among those classiﬁed
as frequent exacerbators in 2003, 5.6% (n = 150) remained in this
category throughout the 5-year period while 16.4% (n = 437)
experienced at least one exacerbation each year during the same
period. The majority (84.6%, n = 2256) had at least 1 year with an
exacerbation, however, almost half of those classiﬁed as frequent
exacerbators at baseline (42.2%, n = 1124), were not classiﬁed as
frequent exacerbators any other year throughout the 5 years of
follow-up (Table 3). Stratiﬁcation by age and sex showed no major
differences, except a slight tendency towards fewer years
classiﬁed as frequent exacerbators among individuals older than
80 years (data not shown).
We conducted a similar analysis assessing the stability over a 3-
year follow-up period, restricting to those with three or more years
of eligible follow-up (n = 13,469, 68.2%). The overall pattern was
generally similar to that of the 5-year analysis (supplementary
table 1). Of those classiﬁed as frequent exacerbators at baseline,
47.9% (n = 1704) were not classiﬁed as frequent exacerbators in
any of the subsequent 3 years, and 20.4% (n = 725) did not have
any exacerbations at all.
DISCUSSION
Main ﬁndings
In this population-based study covering the entire Danish popula-
tion, we included all COPD patients experiencing an exacerbation in
2003 and followed them for up to 10 years. About half of those
classiﬁed as frequent exacerbators in 1 year remained in this
category in the following year, and an increasing proportion was
classiﬁed as non-exacerbators throughout follow-up. At an individual
level, the majority of the population experienced changes in the
exacerbation frequency over time and very few remained frequent
and severe exacerbators during a 5-year follow-up period.
Interpretation of ﬁndings in relation to previously published work
To our knowledge, the stability of the frequent exacerbator over
an extended period is only investigated in the ECLIPSE study. The
ECLIPSE study found that the frequent exacerbator was relatively
stable over a 2-year follow-up period, although the stability
was more distinct among non-exacerbators.9 Contrary to our
study, the ECLIPSE study was restricted to patients with moderate
to very severe COPD treated in a specialist setting, and follow-up
Table 2. One-year mortality according to exacerbation rate in the previous year
All Non-exacerbators Infrequent exacerbators Frequent exacerbators Severe exacerbators
2004 13.2% (2606 of 19,752) 11.1% (1536 of 13,835) 18.1% (1070 of 5917) 19.0% (1873 of 9853)
2005 11.8% (2015 of 17,146) 8.9% (896 of 10,078) 13.0% (489 of 3760) 19.0% (630 of 3308) 23.0% (858 of 3736)
2006 11.0% (1662 of 15,131) 8.2% (768 of 9335) 12.6% (394 of 3139) 18.8% (500 of 2657) 22.7% (692 of 3046)
2007 11.1% (1499 of 13,469) 8.5% (729 of 8572) 13.7% (366 of 2670) 18.1% (404 of 2227) 23.4% (571 of 2441)
2008 10.6% (1267 of 11,970) 7.9% (613 of 7722) 13.1% (299 of 2279) 18.0% (355 of 1969) 23.8% (501 of 2105)
2009 11.1% (1188 of 10,703) 8.3% (591 of 7092) 13.4% (255 of 1898) 20.0% (342 of 1713) 25.0% (437 of 1748)
2010 10.4% (985 of 9515) 7.8% (491 of 6292) 13.1% (219 of 1673) 17.7% (275 of 1550) 22.7% (343 of 1513)
2011 9.9% (843 of 8530) 7.1% (408 of 5708) 13.8% (203 of 1476) 17.2% (232 of 1346) 23.0% (294 of 1276)
2012 10.2% (783 of 7687) 7.6% (390 of 5143) 12.6% (172 of 1370) 18.8% (221 of 1174) 24.8% (281 of 1132)
Non-exacerbators (0 exacerbation in the previous year)
Infrequent exacerbators (1 exacerbation in the previous year)
Frequent exacerbators (≥2 exacerbations in the previous year)
Severe exacerbators (≥1 hospitalization with COPD in the previous year)
Fig. 2 The stability at a population level over time. Riverplot illustrating the stability of the exacerbation rate over time among exacerbators at
baseline. The size of the nodes is proportional to the percentage of individuals classiﬁed as frequent exacerbators, infrequent exacerbators
and non-exacerbators, respectively. The thickness of the links between categories illustrates the size of the ﬂow, i.e., the proportion of COPD
patients within each category who are classiﬁed as either frequent exacerbators, infrequent exacerbators and non-exacerbators in the
following year. The difference in volume between links and nodes represents the number of deaths each year. Red Frequent exacerbators (≥2
exacerbations in the given year); Blue Infrequent exacerbators (1 exacerbation in the given year); Green Non-exacerbators (0 exacerbations in
the given year)
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was limited to 3 years.11 Taking the differences in the study
populations into account, the lack of a stable frequent exacerbator
in the general population as indicated in this study is not
necessarily conﬂicting with the results of the ECLIPSE study. A
recent primary care study has estimated the tendency to remain in
the same GOLD category over time,14 ﬁnding that the majority of
patients in GOLD category D changed to less severe categories
within 12 months of follow-up. This indicates variations in disease
severity over time and as such, indirectly supports our ﬁndings.14
Strengths and limitations of this study
The main strengths of our study is the large sample size and the
nationwide approach with register data covering the entire nation,
providing a unique opportunity to evaluate the stability of
frequent exacerbators in a real-life setting over a long period
through prospectively and independently collected register-based
data from the general population.
According to previous studies, the COPD diagnosis has adequate
completeness and a high positive predictive value (92%) in the
Danish National Patient Register.15 Further, treatment with corti-
costeroids alone or in combination with antibiotics based on the
Prescription Registry is considered a valid measure of COPD
exacerbations in epidemiological studies.16 As such, identifying
patients based on both an exacerbation and use of medication
targeting obstructive pulmonary disease is considered to ensure a
highly valid diagnosis of COPD in our study population.
The main limitation of the study was the lack of spirometry data,
which prohibited a detailed assessment of disease severity. Thus,
we cannot exclude that certain subpopulations of COPD patients
might display a more stable disease trajectory. Similarly, some
COPD patients and exacerbations might be misclassiﬁed as such
when only based on registry data. To this end, we had excluded
individuals <55 years and restricted to those experiencing an
exacerbation requiring medical treatment in 2003. Further, our
annual rate of exacerbations is comparable to a previous Danish
population-based study.17 As such, we ﬁnd it unlikely that a large
proportion of individuals meeting these criteria do not have COPD
and exacerbations. Further, our sensitivity analysis based on a
population of patients who had exacerbations in both 2002 and
2003 led to similar conclusions. In addition, we could not assess to
which extend prescriptions for oral corticosteroids were ﬁlled
ahead of time, i.e., stockpiling. This would result in an over-
estimation of the exacerbation rate at ﬁrst, and later, in an
underestimation. We do not expect this to have a substantial
impact on our results, as prophylactic ﬁllings are rare in Denmark.
Another limitation of the study was that we were not able to
account for the effect of inhaled bronchodilators and inhaled
corticosteroids on the exacerbation rate. Long-acting muscarinic
antagonist, long-acting beta-agonists, and inhaled corticosteroid-
long-acting beta-agonists combinations have been shown to
reduce the risk of exacerbations.18–21 A large proportion of the
population received treatment with inhaled bronchodilators and/
or inhaled corticosteroids at baseline, making it unlikely that a
marked improvement in prognosis can be attributed to more
extensive drug therapy. Further, the reported effect sizes are in
general not assumed to explain frequent exacerbators to return to
a non-exacerbator state and thus cannot explain the observed
exacerbation rates in the present study.18–21
Deﬁning exacerbations by the use of short-term oral corticos-
teroids induces a risk of misclassifying individuals as having
exacerbations when using oral corticosteroids for other indica-
tions. However, the use of short-term oral corticosteroids for other
indications than COPD is uncommon and would result in a slight
overestimation of the rate of exacerbations. Hence, it would not
affect our conclusion. Conversely, our deﬁnition of exacerbations
based on use of oral corticosteroids does not capture untreated
exacerbations as well as exacerbations treated with antibiotics
only. As such, we underestimate the exacerbation rate but limit
the outcome to moderate to severe exacerbations, which are
expected to have the largest impact on the trajectory of COPD. On
the other hand, including antibiotics in the deﬁnition of
exacerbations, as in our sensitivity analyses, overestimates the
exacerbation rate, as no antibiotics are exclusively labeled or used
for exacerbations. However, it is of note, that even with the widest
deﬁnition of exacerbations including all potentially relevant
antibiotics, we observed large variations in the exacerbation rate
(supplementary Fig. 2).
Table 3. Stability at an individual level
Outcome N Percentage Cumulative
All exacerbators (entire cohort)
≥1 exacerbation annually
for 5 out of 5 years 812 7.6% 7.6%
for 3 to 4 out of 5 years 2376 22.2% 29.8%
for 1 to 2 out of 5 years 4197 39.3% 69.0%
for 0 out of 5 years 3318 31.0% 100.0%
≥2 exacerbations annually
for 5 out of 5 years 216 2.0% 2.0%
for 3 to 4 out of 5 years 907 8.5% 10.5%
for 1 to 2 out of 5 years 2901 27.1% 37.6%
for 0 out of 5 years 6679 62.4% 100.0%
Frequent exacerbators at baseline
≥1 exacerbation annually
for 5 out of 5 years 437 16.4% 16.4%
for 3 to 4 out of 5 years 875 32.8% 49.2%
for 1 to 2 out of 5 years 944 35.4% 84.6%
for 0 out of 5 years 410 15.4% 100.0%
≥2 exacerbations annually
for 5 out of 5 years 150 5.6% 5.6%
for 3 to 4 out of 5 years 444 16.7% 22.3%
for 1 to 2 out of 5 years 948 35.6% 57.8%
for 0 out of 5 years 1124 42.2% 100.0%
Severe exacerbators at baseline
≥1 exacerbation annually
for 5 out of 5 years 364 9.5% 9.5%
for 3 to 4 out of 5 years 980 25.5% 35.0%
for 1 to 2 out of 5 years 1485 38.7% 73.7%
for 0 out of 5 years 1008 26.3% 100.0%
≥1 hospitalization annually
for 5 out of 5 years 166 4.3% 4.3%
for 3 to 4 out of 5 years 612 15.9% 20.3%
for 1 to 2 out of 5 years 1469 38.3% 58.6%
for 0 out of 5 years 1590 41.4% 100.0%
The ﬁrst section shows the proportion of individuals who experienced ≥1
exacerbation in year 2003 (i.e. all exacerbators) categorized according to
the number of years in which they experienced ≥1 exacerbation or ≥2
exacerbations, respectively, throughout the ﬁrst 5 years of follow-up. As an
example, 8.5% of the study population, i.e., those who had an exacerbation
in 2003, had ≥2 exacerbations in 3 or 4 years of the ﬁrst 5 years of follow-
up, while 62.4% had no years with ≥2 exacerbations within the same
period. The table similarly shows the proportion of frequent and severe
exacerbators in 2003, respectively, categorized according to the number of
years in which they experienced ≥1 exacerbation, ≥2 exacerbations or ≥1
hospitalization throughout the 5 years of follow-up
Infrequent exacerbators (1 exacerbation in the given year)
Frequent exacerbators (≥2 exacerbations in the given year)
Severe exacerbators (≥1 hospitalization with COPD in the given year)
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Healthy survivor effect is a potential bias in this study, as the
mortality is higher among those classiﬁed as frequent and severe
exacerbators (Table 2). The stability at an individual level could
only be assessed in individuals who survived throughout the 3 or
5 years follow-up, which raises the question whether the skewed
mortality infers a bias towards a less stable phenotype by
selectively removing patients with frequent exacerbations. To this
end, we note that a large proportion of the study cohort was
classiﬁed as non-exacerbators or infrequent exacerbators also
within the ﬁrst years after inclusion where the cumulative
mortality was limited. Consequently, a healthy survivor effect
cannot in itself explain our results. While the cause of death is not
known in our study, other studies have shown that primary causes
of death in mild COPD are cardiovascular diseases and malig-
nancies and, as COPD severity increases, respiratory diseases
become a more frequent cause of death.22, 23 Among patients
with moderate to very severe COPD, non-malignant respiratory
diseases are the cause of death in about 35% of COPD patients.24
As such, we ﬁnd it unlikely that the differences in mortality can
explain our ﬁndings.
Implications for future research, policy and practice
This study indicates that the trajectory of COPD in the general
population is not necessarily progressive, at least with respect to
exacerbation frequency. This might hold implications for treat-
ment guidelines targeting COPD patients outside a specialist
setting and for the practical application of these guidelines among
patients with ﬂuctuating disease severity. However, we acknowl-
edge that our ﬁndings are controversial and consequently that
they need to be conﬁrmed in other populations and settings.
CONCLUSIONS
In conclusion, this real-life study found considerable variations in
the exacerbation rate over time and indicates that the majority of
COPD patients in the general population do not persist with
frequent exacerbations as a stable feature of their disease.
METHODS
We conducted a nationwide register-based epidemiological study with a
10-year follow-up period comprising all Danish patients with COPD who
had at least one exacerbation in 2003.
Data sources
Data were retrieved from Statistics Denmark, which is a governmental
institution collecting electronic records for a broad spectrum of statistical
and scientiﬁc purposes. The registries cover the entire Danish population of
5.4 million people (in 2003), of whom 1.5 million were 55 years or older, and
contain detailed longitudinal register data at an individual level.25, 26 All
Danish citizens are assigned with a unique civil registration number, which is
used in all records and enables ﬂawless linkage between registries.26, 27
The Danish National Patient Register contains administrative data on all
hospital admissions since 1977 and contacts to outpatient clinics since
1995. The register contains information on date of admission and
discharge diagnoses (ICD-10 since 1994).28, 29 The National Prescription
Registry records information on medication for outpatient use sold on
prescription since 1995.30 Each record includes date of purchase and the
quantity dispensed. The dosing information and the indication for
prescribing is not available as well as drugs dispensed at hospital level.
Drugs are classiﬁed according to WHO’s anatomical-therapeutic-chemical
(ATC) system and the quantity dispensed for each prescription is given by
the number, strength and deﬁned daily dose of the pharmaceutical
entities. All medications targeting obstructive pulmonary disease (ATC R03)
as well as corticosteroids (ATC H02) require a prescription.
Population
We identiﬁed a closed cohort of individuals with at least one exacerbation
requiring medical treatment from 1 January 2003 to 31 December 2003.
We further required that individuals were ≥55 years and ﬁlled at least one
prescription for medication targeting obstructive pulmonary disease (ATC
R03) within 2003 (see Appendix 1). The composite requirement of high
age, exacerbation status and the use of medication targeting obstructive
pulmonary disease was applied to reduce the risk of including individuals
with asthma in the COPD cohort. Further, the closed cohort of patients
with exacerbations in 2003 allowed us to describe the trajectory of a
patient population for 10 years. Inclusion and follow-up of one-year COPD
exacerbators was estimated to account for roughly 5–7% of the total COPD
population in Denmark.
Deﬁnition of exacerbation rate
We deﬁned a patient experiencing an exacerbation as a patient ﬁlling a
prescription for a short-term course of oral corticosteroids (OCS) or being
hospitalized due to COPD. Prescriptions of OCS and/or hospitalization had
to be separated by 4 weeks to be considered separate events. This
deﬁnition has previously been used in population-based studies17, 31 and is
considered valid in an epidemiological setting.15, 16 A detailed deﬁnition of
exacerbations is supplied in Appendix 2. Since indications for the use of
medications are not available in the National Prescription Registry, we were
unable to separate prescriptions targeted at exacerbations from prescrip-
tions targeted at other infectious events. Therefore, exacerbations treated
with antibiotics alone were not included in the primary analysis. Recognizing
that exacerbations are sometimes treated with antibiotics alone, we
performed two sensitivity analyses where we included prescriptions for
antibiotics in the deﬁnition of exacerbations. First, we exclusively included
prescriptions for amoxicillin and clavulanic acid (an enzyme inhibitor), as this
is the recommended ﬁrst-line antibiotic treatment of exacerbations in
Denmark.32 Next, we included prescriptions for the most frequently used
antibiotics in the treatment of exacerbations.33
According to the occurrence of exacerbations in a given calendar year,
patients were classiﬁed as (1) non-exacerbators: 0 exacerbations, (2)
infrequent exacerbators: 1 exacerbation, or (3) frequent exacerbators: ≥2
exacerbations. Further, we categorized patients with one or more
hospitalizations due to COPD as severe exacerbators31, 34 Thus, severe
exacerbators are either frequent or infrequent exacerbators.
Analysis
To analyze baseline characteristics of exacerbators, we assessed registry
data on age, sex and use of R03 medicine by the end of the inclusion
period (31 December 2003). Individuals were classiﬁed as ﬁrst time
exacerbators or previous exacerbators, based on whether or not they had
experienced at least one exacerbation in the 5 years prior to inclusion; i.e.,
in 1998–2002. To describe characteristics of the frequency of exacerbations
and mortality over time, we determined the distribution of frequent
exacerbators, infrequent exacerbators, non-exacerbators and individuals
lost to follow-up each year from 2004 to 2012.
The stability of the frequent exacerbator phenotype was assessed using
two different approaches. First, we classiﬁed exacerbators in 2003 as
frequent exacerbators, infrequent exacerbators or non-exacerbators each
year from 2004 to 2012, and estimated the ﬂow between categories by
calculating the annual proportion within each category that was classiﬁed
as frequent exacerbators, infrequent exacerbators or non-exacerbators or
was lost to follow-up (died or migrated) in the subsequent year. We
performed a supplementary analysis restricting the population to
individuals classiﬁed as frequent exacerbators in 2003.
As this analysis does not reveal the individuals’ tendency to remain in
the same category more than 1 year, we secondly assessed the stability of
frequent and severe exacerbators at an individual level during a 5-year
follow-up period. To this end, we calculated the proportion of frequent
exacerbators at baseline who remained classiﬁed as frequent exacerbators
in 0, 1–2, 3–4 or 5 years or were classiﬁed as infrequent or frequent
exacerbators in 0, 1–2, 3–4 or 5 years. Further, we calculated the proportion
of individuals who remained classiﬁed as severe exacerbators for 0, 1–2,
3–4 or 5 years. This analysis was restricted to those eligible for follow-up
throughout the entire 5-year period, and as such, the results from this
analysis is sensitive to the considerable mortality among COPD patients. To
test the inﬂuence of this restriction, we conducted a similar analysis using a
3-year follow-up period.
We performed supplementary analyses in which we stratiﬁed by sex and
age (55–69, 70–79 and 80 + years at baseline). These categories represent
birth cohorts with different exposures to risk factors for COPD (e.g., smoking
and occupation) and potentially diverse trajectories of disease.
Stability of the frequent COPD exacerbator
M Reilev et al.
5
Published in partnership with Primary Care Respiratory Society UK npj Primary Care Respiratory Medicine (2017)  25 
All analyses were performed using STATA 14.0 (StataCorp, College
Station, TX, USA).
The study was approved by the Danish Data Protection Agency.
According to Danish legislation, neither approval from the ethics
committee nor informed consent from the study populations is required
for registry-linkage studies.28
Data availability
Analytical programs are available, while access to the dataset requires an
application to The Danish Health Data Authorities.
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